

Kurzprotokoll
GMMG-HD-10/DSMM XX

Öffentlicher Titel	A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide and Dexamethasone with and without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
Wissenschaftl. Titel	A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide and Dexamethasone with and without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
Kurztitel	GMMG-HD-10/DSMM XX
Titel am Standort	Freiburg, CCCF: GMMG-HD-10/DSMM XX
Studienphase	Phase II
Erkrankung	Haema: Multiples Myelom: Erstlinie
Alter	Erwachsene ohne Altersbegrenzung
Status	Aktiv
Prüfzentren	Freiburg: Tumorzentrum - Comprehensive Cancer Center Freiburg Philipp Zart
Sponsorart	Industrie Studie
Registrierung in anderen Studienregistern	Europäisches Studienregister 2022-001186-12
Links	Weiterführende Informationen (EudraCT) (https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001186-12/DE)

Einige Angaben stellen Näherungswerte dar (z.B. Alter). Die genaueren Angaben finden Sie unter 'Links'.